"Quadruple Rule-Out" With Computed Tomography in a COVID-19 Patient With Equivocal Acute Coronary Syndrome Presentation.
Gianluca Pontone, Andrea Baggiano, Edoardo Conte...
https://pubmed.ncbi.nlm.nih.gov/32762888/Actively Recruiting
Led by IRCCS San Raffaele · Updated on 2026-01-15
123
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying interstitial lung diseases ILDs, a group of chronic conditions that cause serious lung and heart problems, including early heart complications that often go unnoticed. These heart issues can include ischemic heart disease, worsening of artery health, and right heart dysfunction due to high lung blood pressure. Early detection and accurate assessment of both lung and heart damage are important to prevent disease worsening and improve patient outcomes. The study is observational and uses advanced multidimensional and ultra-high resolution computed tomography CT scans to non-invasively evaluate and measure lung and heart damage in patients with progressive fibrosing ILDs. The goal is to develop a low-dose CT imaging protocol that can characterize lung tissue changes and discover new imaging biomarkers of lung disease severity. Additionally, researchers aim to study the prevalence and types of heart disease in ILD patients and create a CT-based risk assessment tool. Participants will undergo CT scans over a period of months to measure lung and heart conditions using these new imaging methods. The main focus is to assess lung tissue damage between months 2 and 12, then evaluate heart disease features and their link to lung severity between months 3 and 16. Later, a multiparametric CT algorithm for risk stratification will be developed from months 19 to 24. Throughout the study, data collection will be done with informed consent, and participants will be monitored for safety and disease progression.
CONDITIONS
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
A
Anna Palmisano
A
Antonio Esposito Esposito
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
IRCCS San Raffaele
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants undergo advanced multidimensional and ultra high resolution computed tomography to assess cardiopulmonary involvement in their lung disease.
Imaging visits occurring between months 2 and 24
Duration - Up to 24 months
Participants are observed over time to evaluate disease progression and cardiac injury related to their lung condition.
Periodic assessments up to month 24
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Gianluca Pontone, Andrea Baggiano, Edoardo Conte...
https://pubmed.ncbi.nlm.nih.gov/32762888/Ganesh Raghu, Valeria C Amatto, Jürgen Behr...
https://pubmed.ncbi.nlm.nih.gov/26424523/Anna Palmisano, Davide Vignale, Marijana Tadic...
https://pubmed.ncbi.nlm.nih.gov/34874200/Davide Vignale, Anna Palmisano, Caterina Colantoni...
https://pubmed.ncbi.nlm.nih.gov/36165795/Yann Gaillandre, Alain Duhamel, Thomas Flohr...
https://pubmed.ncbi.nlm.nih.gov/37071165/Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers...
https://pubmed.ncbi.nlm.nih.gov/30168753/Anna Palmisano, Chiara Gnasso, Alberto Cereda...
https://pubmed.ncbi.nlm.nih.gov/37166497/Athol U Wells, Kevin K Brown, Kevin R Flaherty...
https://pubmed.ncbi.nlm.nih.gov/29773608/Jaume Sauleda, Belén Núñez, Ernest Sala...
https://pubmed.ncbi.nlm.nih.gov/30501130/Saurabh Gupta, Prasanta Padhan, Saswat Subhankar...
https://pubmed.ncbi.nlm.nih.gov/34760753/IRCCS San Raffaele
Lead Sponsor